Rafiq Hasan, Complement Therapeutics CEO
April 17, 2023 01:30 AM EDT
Financing
Startups
Cell/Gene Tx

VCs 'Com­ple­men­t' Eu­ro­pean biotech with $79M for reti­nal AAV gene ther­a­py tri­al next year

Kyle LaHucik

Senior Reporter

Com­ple­ment Ther­a­peu­tics raised a €72 mil­lion ($79.6 mil­lion) Se­ries A to bankroll a Phase Ib of its AAV gene ther­a­py in ge­o­graph­ic at­ro­phy.

The dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times